ONE Bio Obtains Key Certification Allowing for Increased Production of Highly Demanded Botanical Extracts
MIAMI, FL--(Marketwire - December 2, 2009) - ONE Bio, Corp. ("ONE" or the "Company") (formerly ONE Holdings, Corp.) (
Sarcandra Glabra is a valuable plant whose extracts are used in a variety of health and wellness products. Earlier this year ONE Bio's subsidiary filed an invention patent for extracting Isofraxidin and Flavonoid from Sarcandra Glabra. Sarcandra Glabra is used in traditional Chinese medicine for many treatments including bruising, bone fractures, arthritis, nausea, internal pain, and cough. It has also been proposed for the treatment of chemotherapy-induced thrombocytopenia.
Polygonum Cuspidatum is known to some as "Japanese Knotweed" which Resveratrol is a key extract. Resveratrol is a highly demanded raw extract believed to have various health benefits. Resveratrol is an active component and a powerful antioxidant. It is extensively used for treatment and research of various cancers and Alzheimer's disease.
"These certifications will help us greatly increase our botanical production capacity. Sarcandra Glabra and Polygonum Cuspidatum extracts are in high demand and both are difficult to cultivate. Our region in China was named the Sarcandra capital which makes our land extremely valuable," stated ONE's China President Min Zhao.
"Our R&D group continues to innovate and maintain the highest quality in herbal and chemical extracts," stated ONE's CEO Marius Silvasan. "This quality has helped us earn various key certifications boosting our product portfolio," added Silvasan.
About ONE Bio, Corp.
ONE Bio, Corp. ("ONE") (
About Green Planet Bioengineering, Co., Ltd.
Green Planet Bioengineering CO., LTD. ("Green Planet") ([ http://www.greenplanetbio.com ]) (
This press release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). ONE Bio, Corp. claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," or "anticipates," and do not reflect historical facts. Specific forward-looking statements contained in this press release include, but are not limited to: our successful integration of diversified growth companies, impact of the company's expansion plan, and new business development success, future financial results, development and acquisition of new product lines and services, the impact of competitive products or pricing from technological changes, the effect of economic conditions and other uncertainties. The forward-looking statements contained herein involve risks and uncertainties that could cause actual results to differ materially from the expectations contained in any such forward-looking statements. These risks include, but are not limited to: failure to manage operating expenses or integrate new companies and/or technologies, each of which could have a material impact on our business, our financial results, and the company's stock price. These risks and other factors are detailed in the Company's regular filings with the U.S. Securities and Exchange Commission. Most of these factors are difficult to predict accurately and are generally beyond the Company's control. Forward-looking statements speak only as to the date they are made and ONE Bio, Corp. does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.